Literature DB >> 11493435

T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.

E Alyea1, E Weller, R Schlossman, C Canning, I Webb, D Doss, P Mauch, K Marcus, D Fisher, A Freeman, B Parikh, J Gribben, R Soiffer, J Ritz, K Anderson.   

Abstract

Previous trials of allogeneic bone marrow transplantation (BMT) in patients with multiple myeloma (MM) have demonstrated high response rates but also high transplantation-related mortality (TRM) and high relapse rates. Exploitation of this strategy remains of interest because donor lymphocyte infusions (DLIs) can induce a potent graft-versus-myeloma (GVM) effect. CD6 T-cell--depleted allogeneic BMT was combined with prophylactic CD4(+) DLI administered 6 to 9 months after BMT in an effort to reduce TRM and to induce a GVM response after BMT. Twenty-four patients with matched sibling donors and chemotherapy-sensitive disease underwent BMT. CD6 T-cell depletion of donor bone marrow was the sole method of graft-versus-host disease (GVHD) prophylaxis. GVHD after BMT was minimal, 1 (4%) grade III and 4 (17%) grade II GVHD. Fourteen patients received DLI, 3 in complete response and 11 with persistent disease after BMT. Significant GVM responses were noted after DLI in 10 patients with persistent disease, resulting in 6 complete responses and 4 partial responses. After DLI, 50% of patients developed acute (> or = II) or extensive chronic GVHD. Two-year estimated overall survival and current progression-free survival (PFS) for all 24 patients is 55% and 42%, respectively. The 14 patients receiving DLI had an improved 2-year current PFS (65%) when compared with a historical cohort of MM patients who underwent CD6-depleted BMT survived 6 months with no GVHD and did not receive DLI (41%) (P =.13). Although this study suggests that prophylactic DLI induces significant GVM responses after allogeneic BMT, only 58% of patients were able to receive DLI despite T-cell--depleted BMT. Therefore, less toxic transplantation strategies are needed to allow a higher proportion of patients to receive DLI and the benefit from the GVM effect after transplantation. (Blood. 2001;98:934-939)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493435     DOI: 10.1182/blood.v98.4.934

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

Review 1.  Bone marrow immunohistology of plasma cell neoplasms.

Authors:  A Wei; S Juneja
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.

Authors:  Alexandra Gomez-Arteaga; Gunjan L Shah; Raymond E Baser; Michael Scordo; Josel D Ruiz; Adam Bryant; Parastoo B Dahi; Arnab Ghosh; Oscar B Lahoud; Heather J Landau; Ola Landgren; Brian C Shaffer; Eric L Smith; Guenther Koehne; Miguel-Angel Perales; Sergio A Giralt; David J Chung
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-23       Impact factor: 5.742

3.  Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Authors:  Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Hong-Bin Fang; Ling Cai; Stephen Janofsky; Anne Chew; Jan Storek; Gorgun Akpek; Ashraf Badros; Saul Yanovich; Ming T Tan; Elizabeth Veloso; Marcela F Pasetti; Alan Cross; Sunita Philip; Heather Murphy; Rita Bhagat; Zhaohui Zheng; Todd Milliron; Julio Cotte; Andrea Cannon; Bruce L Levine; Robert H Vonderheide; Carl H June
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 4.  Novel approaches in allogeneic stem cell transplantation.

Authors:  Esperanza B Papadopoulos; Ann A Jakubowski
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 5.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

6.  Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.

Authors:  Roberto Bellucci; Sabine Oertelt; Meagan Gallagher; Sigui Li; Emmanuel Zorn; Edie Weller; Fabrice Porcheray; Edwin P Alyea; Robert J Soiffer; Nikhil C Munshi; M Eric Gershwin; Jerome Ritz
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 7.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

Review 8.  Recent developments in hematopoietic stem cell transplantation for multiple myeloma.

Authors:  William I Bensinger
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

9.  CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.

Authors:  Eric Smith; Sean M Devlin; Satyajit Kosuri; Evelyn Orlando; Heather Landau; Alex M Lesokhin; David J Chung; Hani Hassoun; Nikoletta Lendvai; Ola Landgren; Sergio Giralt; Ajai Chari; Sundar Jagannath; Guenther Koehne
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-30       Impact factor: 5.742

Review 10.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.